gms | German Medical Science

56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e. V. (DGNC)
3èmes journées françaises de Neurochirurgie (SFNC)

Deutsche Gesellschaft für Neurochirurgie e. V.
Société Française de Neurochirurgie

07. bis 11.05.2005, Strasbourg

Memory T cells in peripheral blood and bone marrow of glioblastoma patients

Nachweis von Gedächtnis-T-Zellen im Blut und Knochenmark von Glioblastompatienten

Meeting Abstract

  • corresponding author R. Ahmadi - Neurochirurgische Universitätsklinik Heidelberg
  • R. Ranaie - Neurochirurgische Universitätsklinik Heidelberg
  • H. H. Steiner - Neurochirurgische Universitätsklinik Heidelberg
  • A. Unterberg - Neurochirurgische Universitätsklinik Heidelberg
  • P. Beckhove - DKFZ, Abteilung Zelluläre Immunologie, Heidelberg
  • C. Herold-Mende - Neurochirurgische Universitätsklinik Heidelberg

Deutsche Gesellschaft für Neurochirurgie. Société Française de Neurochirurgie. 56. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3èmes journées françaises de Neurochirurgie (SFNC). Strasbourg, 07.-11.05.2005. Düsseldorf, Köln: German Medical Science; 2005. DocP166

The electronic version of this article is the complete one and can be found online at: http://www.egms.de/en/meetings/dgnc2005/05dgnc0434.shtml

Published: May 4, 2005

© 2005 Ahmadi et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective

In the bone marrow of patients with mammary carcinoma an increased number of tumor-reactive memory T cells has been shown. These cells could be reactivated in vitro and therapeutically used in vivo. Aim of the present study was to analyze, whether tumor-reactive memory T cells can also be found in brain tumor patients and in which immunological compartments these cells are enriched.

Methods

By IFN-γ Elispot assay and kill assay we analyzed peripheral blood (n=31) and bone marrow (n=12) of glioblastoma patients. IFN-γ Elispot served to identify the percentage of specific memory T cells per 106 T cells in these two compartments. Kill assay was used for functional testing of tumor-cytotoxic activity of these cells in vitro.

Results

12/31 patients presented in the peripheral blood with a significantly increased number of tumor-reactive memory T cells. In 5/12 patients these cells could also be found in the bone marrow. Using bone marrow memory T cells an exemplarily performed 4 h chromium release cytotoxicity assay with cultivated tumor cells revealed a tumor specific lysis of 15.5%±2,5% of the tumor cells compared to 2.2%±1,1% in the specificity control. With memory T cells of the peripheral blood we obtained values of 7.5%±1,0% compared to 1.5%±0,8% in the specificity control.

Conclusions

Tumor-reactive memory T cells can be proven in the peripheral blood as well as in the bone marrow of glioblastoma patients and can possess tumor-toxic activity. The use of a NOD/Scid mouse model is planned for further evaluation of their therapeutical potential in vivo.